This is Emulate’s first time being chosen by Fierce Medtech’s for their annual selection of the 15 most innovative, creative, “Fierce” companies in the med tech industry.
Boston, MA – March 7, 2022 – Emulate, Inc., a leading provider of next-generation in vitro models, today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
“We are honored to be among this group of innovative medtech companies for the first time this year,” said Emulate CEO Jim Corbett. “Our success can be attributed to a team that is committed to setting a new standard for the drug discovery and development process through the use of Organ-Chip technology. By empowering the research community to explore mechanisms of health and disease using in vitro models that emulate biology and predict human response, we hope to reduce the need for animal testing and enable the development of safer and more effective drugs.”
During the past year, Emulate achieved several significant milestones that helped to advance its mission to improve human health through a deeper understanding of human biology. The completion of the single largest Organ-Chip study to date demonstrated that the use of the human Liver-Chip could improve patient safety and better predict drug toxicity than other methods for modeling drug-induced liver injury. They launched both their Colon Intestine-Chip and Brain-Chip, which was sent to the International Space Station to study the effects of microgravity on human brain physiology as part of the Tissue-Chips in Space initiative. Emulate also strengthened its commitment to leveraging Organ-Chip technology as an alternative to animal testing by supporting various legislation and policy initiatives.
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Medtech’s 10th annual Fierce 15 selection. This year’s full list of winners can be viewed online here.
“While we’re not fully out of the woods yet when it comes to COVID-19, the innovations pursued by this year’s class of 15 companies will help the industry evolve, either in step with the pandemic or in spite of it,” said Conor Hale, senior editor of Fierce Medtech.
An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Medtech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
For more information on Emulate, please visit emulatebio.com
About Emulate, Inc.
Emulate is igniting a new era in human health with industry-leading Organ-on-a-Chip technology. The Human Emulation System provides a window into the inner workings of human biology and disease — offering researchers an innovative technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Pioneered at the Wyss Institute for Biologically Inspired Engineering at Harvard University and backed by Northpond Ventures, Founders Fund, and Perceptive Advisors, Organ-on-a-Chip technology is assisting researchers across academia, pharma, and government industries through its predictive power and ability to recreate true-to-life human biology. To learn more, visit emulatebio.com or follow us on LinkedIn and Twitter.
Media Contact:
Rebecca Willumson
Fierce Medtech
202-824-5050
rwillumson@questex.com
Michael Sullivan
Emulate, Inc.
+1 503-799-7420
michael@teamseismic.com
